Stock & Company Details
Geron Corp. $GERN
Price:
N/A
N/A
642M
$622M
52 Week High:
N/A
10 Day Average Volume:
N/A
-9.36
50 Day Moving Average:
N/A
52 Week Low:
N/A
30 Day Average Volume:
N/A
N/A
N/A
N/A
30 Day Change:
N/A
3 Month Change:
N/A
Health Technology
GERN technical indicators
Latest Geron Corp. (GERN) indicator readings as of 2026-10-29.
GERN's 14-day RSI is 25.0, in oversold territory. At $0.95 it is trading 33.7% below its 200-day moving average of $1.43, and below its 50-day average of $1.30. Price sits below the lower Bollinger Band ($1.01 to $1.32). ADX reads 34.5, indicating a trending market.
Overview
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's leading drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses global rights to this drug. the company operates as a single segment, the development of therapeutic products for oncology.
Finance Bot
Ask your questions
Start by typing a question below.
